Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02829723 · ClinicalTrials.gov registry record · Phase 1
A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 192
- Enrollment target
NCT02829723 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 192 participants.
The verdict
NCT02829723, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 192 participants
- Enrollment target
Study Summary
The purpose of this first-in-human (FIH) study of BLZ945 given as a single agent or in combination with PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLZ945, administered orally, as a single agent or in combination with PDR001, administered intravenously (i.v.) in adult patients with advanced solid tumors.
Interventions
- DRUG PDR001
- DRUG BLZ945
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2016-10-21 |
| Est. Completion | 2022-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02829723
The ClinicalTrials.gov registry entry for NCT02829723 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PDR001 is the first listed.
NCT02829723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02829723 about?
NCT02829723 is a clinical study titled "A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors". The purpose of this first-in-human (FIH) study of BLZ945 given as a single agent or in combination with PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLZ945, administered orally, as a single agent or in combination with PDR00...
What is the current status of trial NCT02829723?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 192 participants. The study started on 2016-10-21. Estimated completion is 2022-12-01.
What interventions are being tested in trial NCT02829723?
The interventions under investigation include: PDR001 (DRUG), BLZ945 (DRUG).
Who is sponsoring clinical trial NCT02829723?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.